Rival vaccines are being tested in a series of African trials to measure their effectiveness in treating the Ebola virus and acting as a vaccine, Reuters reports. The vaccines have been developed by GlaxoSmithKline and a new company, New Link Genetics. Both vaccines are in an early stage of testing, but have both so far proved helpful in producing large amounts of anti Ebola antibodies in the individuals they have been tested on. Susan McGalla suggests that the two vaccines are both provided as a single injection and have been tested on a group of 600 people in Liberia, with an extended trial now being begun to see how the vaccine’s work in a large group of people.
The Ebola crisis of 2014 sparked a large amount of research into producing a vaccine to fight the virus, which is said to have been responsible for over 10,000 deaths in West Africa during the recent outbreak. The next step in testing will come when a larger test group is sourced who will be provided with a placebo or one of the two vaccines to test which is the most effective. Officials in charge of the trials are hoping to encourage more women to take part in the trials as only 16 percent of those in the initial tests were female.